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Abstract: Attention Deficit Hyperactivity Disorder (ADHD) is a childhood psychiatric condition characterized by severe 
impulsiveness, inattention and overactivity. Methylphenidate (MPH), a psychostimulant affecting both the dopaminergic 
and the noradrenergic systems, is one of the most frequently prescribed treatments for ADHD. Despite the widespread use 
of MPH and its proven effectiveness, its precise neurochemical mechanisms of action are under debate. For the most part, 
MPH’s influence on subcortical dopamine neurotransmission is thought to play a crucial role in its behavioral and cogni-
tive effects. In their hypothesis of biphasic MPH action, Seeman and Madras [42, 43] suggest that therapeutic doses of 
MPH elevate tonic dopamine while inhibiting phasic transmitter release in subcortical structures, leading to reduced post-
synaptic receptor stimulation and psychomotor activation in response to salient stimuli. Volkow and colleagues [56] sug-
gest that by amplifying a weak striatal dopamine signal, MPH increases the perception of a stimulus or task as salient. The 
enhanced interest for the task is thought to increase attention and improve performance. Recent animal studies have how-
ever shown that when administered at doses producing clinically relevant drug plasma levels and enhancing cognitive 
function, MPH preferentially activates dopamine and noradrenaline efflux within the prefrontal cortex relative to the sub-
cortical structures [5]. Overall, we suggest that the delineated theories of MPH therapeutic action should not be discussed 
as exclusive. Studies are outlined that allow integrating the different findings and models. 
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INTRODUCTION 
  Attention Deficit Hyperactivity Disorder (ADHD) is a 
childhood psychiatric condition characterized by severe im-
pulsiveness, inattention and overactivity, often resulting in 
long-term educational and social disadvantage [50]. There is 
an ongoing debate concerning the core dysfunctions in 
ADHD, with the main stream of neuropsychological research 
putting emphasis on deficits in arousal (early stage informa-
tion processing), activation (response preparation and readi-
ness to respond), response inhibition and reward responding 
(for a review see [37]).  
  The neural pathways underlying these deficits point 
mostly to frontal-subcortical catecholamine networks. More 
precisely, the nigrostriatal dopamine pathway projecting 
from the substantia nigra to the basal ganglia (caudate nu-
cleus and putamen) is involved in motor control [47]. The 
mesolimbic dopamine pathway, projecting from the ventral 
tegmental area (VTA) to subcortical limbic regions (e.g. nu-
cleus accumbens, olfactory tubercle and amygdala) is in-
volved in motivated behavior and reinforcement learning (for 
a review see [24, 41]). The mesocortical dopamine pathway, 
also originating in the VTA, and projecting to the prefrontal 
cortex, is involved in cognitive functioning [17]. Eventually, 
noradrenergic projections ascending from the locus coer-
uleus to subcortical and cortical structures are involved in 
arousal and cognitive functioning [4, 6, 7]. 
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  Methylphenidate (MPH), a psychostimulant affecting 
both the dopaminergic and the noradrenergic systems, is one 
of the most frequently prescribed treatments for ADHD. In 
the 1930s, Charles Bradley first used a psychostimulant (the 
amphetamine sulfate benzedrine) as part of a workup of 
normally healthy children with neurological and behavioral 
problems. Although Bradely’s intention was to treat post-
lumbar puncture headaches, he was surprised to find a dra-
matic improvement in the children’s learning and behavior. 
However, given that the use of medication in children was 
extremely controversial at that time, the discovery of benze-
drine was largely ignored until MPH was found to be effec-
tive in the treatment of children with attention disorders in 
the 1960s (for a review see [46]). In ADHD patients, MPH 
reduces symptoms of impulsiveness, overactivity and inat-
tention in up to 70% of affected children [23, 49]. Typical 
positive performance effects in healthy adults following sin-
gle oral MPH doses include the improvement of vigilance, 
reaction time and working memory [8, 11, 13, 36]. Although 
the drug has been used for decades, the neural mechanisms 
underlying its – initially contraintuitive – clinical actions are 
still unknown. 
  Aim of the present review is to outline the most dis-
cussed catecholaminergic theories on the functionality of 
MPH in ADHD, and to present some preliminary data on 
MPH function in healthy volunteers. 
NEUROCHEMICAL MECHANISMS OF MPH 
  Despite the widespread use of MPH today – in Canada 
MPH prevalence in children aged 2 to 11 years ranged from 
0.09% to 3.89% between 1994 and 1995 [40] – its precise 
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the most part, MPH’s influence on dopamine neurotransmis-
sion is thought to play a crucial role in its behavioral and 
cognitive effects. The indirect dopamine agonist binds to the 
dopamine transporter (DAT). The DAT is the main mecha-
nism by which the dopamine terminal removes dopamine 
released in response to a salient stimulus. By regulating the 
concentration of dopamine in the synapse, the DAT deter-
mines both the magnitude and the duration of the dopa-
minergic signal. Therefore, MPH-induced blockade of the 
DAT increases dopamine concentrations in the synapse and 
extracellular space [56]. Given an estimated median effective 
dose of 0.25mg/kg for oral MPH, therapeutic drug doses 
(0.3-0.6mg/kg) can be expected to occupy more than 50% of 
the DAT [57]. Highest specific MPH binding was found in 
terminal regions of the nigrostriatal and mesolimbic path-
ways (caudate-putamen, nucleus accumbens, olfactory tuber-
cle and bed nucleus of the stria terminalis) [52]. These do-
pamine-rich subcortical structures have accordingly been 
hypothesized to mediate the drug’s clinical actions [42,   
43, 56]. However, next to its dopamine-specific influence, 
MPH increases extracellular levels of the neurotransmitter 
noradrenaline by blocking its reuptake [18, 29]. Using mi-
crodialysis in rats, Berridge and colleagues [5] showed that 
low-dose MPH activates catecholamine neurotransmission 
within prefrontal structures. When administered at doses 
producing clinically relevant drug plasma levels and enhanc-
ing cognitive function, MPH preferentially activated dopa-
mine and noradrenaline efflux within the prefrontal cortex 
relative to the subcortical nucleus accumbens. Since at the 
present time no radioligands are known to image the 
noradrenaline transporter, and imaging procedures are unable 
to reliably visualize the low levels of dopamine and 
noradrenaline actions in the cortex, the relevance of MPH’s 
noradrenergic and cortical effects has however not been in-
vestigated using functional imaging.
  Next to effects on activity and self-regulation, increases 
in heart rate and blood pressure are characteristic side effects 
of MPH after single oral and intravenous drug doses as well 
as after long-time treatment [38, 51, 58]. Although these 
cardiovascular drug effects have been linked mainly to the 
noradrenergic system, changes in striatal dopamine seem to 
be crucially involved [58]. Moreover, MPH affects mood 
and arousal. Generally, the subjective drug effects are be-
lieved to be more reliably provoked by large and fast dopa-
mine increases (as after insufflation or intravenous drug ad-
ministration) [55], but nevertheless have been shown to oc-
cur after administration of oral doses [9].
THEORIES ON THE FUNCTIONALITY OF MPH IN 
ADHD 
  Two hypotheses have been proposed to explain the clini-
cal relevance of subcortical DAT blockade by MPH. The 
first hypothesis suggests that subsequent to DAT blockade, 
increased extracellular dopamine activates only the very sen-
sitive presynaptic dopamine autoreceptors, which will lead to 
an attenuation of dopamine release in response to a salient 
stimulus [42, 43]. The second hypothesis suggests that in-
creased extracellular dopamine subsequent to DAT blockade 
overcomes the inhibitory effects for activation of the presyn-
aptic autoreceptors, leading to a net effect of dopamine ac-
cumulation in the synapse and subsequent amplification of 
dopamine signals [56]. Eventually, a third hypothesis shifts 
the focus from subcortical dopaminergic to prefrontal nora-
drenergic mechanisms in explaining MPH’s clinical actions 
[2, 5]. 
Hypothesis of Biphasic MPH Action 
  Seeman and Madras [42, 43] suggest that the therapeuti-
cal relevance of subcortical DAT blockade by MPH is based 
on the drug’s biphasic action. Their hypothesis of biphasic 
MPH action, which builds on Grace’s tonic/phasic model of 
dopamine system regulation, aims to explain why psychomo-
tor activity is reduced by low doses, and increased by high 
doses of psychostimulants. 
  According to Grace [19, 20], phasic release refers to the 
transient release of dopamine, produced by action potentials 
of dopamine neurons in response to behaviorally relevant 
external stimuli. Phasic release is competent to set free do-
pamine levels in the >M range [35]. This large but brief 
pulse of dopamine into the synaptic cleft is suggested to ac-
tivate postsynaptic dopamine receptors and evoke dopamine-
dependent behavioral responses [16, 22]. Before phasic do-
pamine diffuses into the extrasynaptic space, it is removed 
from the synaptic cleft by high capacity re-uptake systems 
within seconds. Unlike spike-dependent neurotransmitter 
increases reached within the synaptic cleft, dopamine levels 
in extrasynaptic fluid range between only 10-50nM [10, 44]. 
This extrasynaptic neurotransmitter concentration is under 
strong homeostatic control, as it is maintained even after the 
6-hydroxydopamine (OHDA)-induced depletion of up to 
80% of striatal dopamine [1, 39]. Despite present in low 
concentration, extrasynaptic dopamine seems to cause a 
steady-state partial activation of D2-like dopamine autore-
ceptors, which are located on dopamine neuron terminals. 
Any changes in extrasynaptic neurotransmitter levels are 
detected and counterregulated by these sensitive autorecep-
tors. Because of its tight control and slow time course of 
change, this phenomenon has been labeled tonic dopamine 
regulation [19]. Tonic dopamine release is regulated via pre-
synaptic N-methyl-d-aspartate (NMDA) receptors in a spike-
independent manner by glutamatergic prefrontal cortical 
afferents. As illustrated above, the presence of tonic dopa-
mine in the extrasynaptic space provides a background 
stimulation of the sensitive presynaptic dopamine autorecep-
tors. Abnormal activation of these autoreceptors will trigger 
inhibition of neurotransmitter synthesis [25] and attenuation 
of phasic release [15]. 
  Seeman and Madras [42, 43] argue that the basal or rest-
ing level of extracellular subcortical dopamine is approxi-
mately 4nM, and transiently rises at least 60-fold to about 
250nM during a normal nerve impulse. This elevated level of 
extracellular dopamine falls back to 4nM within millisec-
onds, primarily by diffusion, but assisted by the dopamine 
transporter. When the DAT is blocked in the presence of a 
low therapeutic MPH dose, the resting level of extracellular 
dopamine rises by about 6-fold. This elevated resting state 
dopamine level is hypothesized to act on the presynaptic 
dopamine D2-like autoreceptors and consequently reduce the 
relative rise in impulse-triggered dopamine release to only 
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sponse to a salient stimulus would therefore result in less 
activation of postsynaptic dopamine D1 and D2-like recep-
tors, eventually resulting in reduced psychomotor activity in 
response to the stimulus. In accordance with this hypothesis, 
low doses of MPH have been shown to suppress locomotor 
activity in the rat under conditions associated with elevated 
arousal [31], similar to what is observed in ADHD. At higher 
MPH doses, the magnitude of the increase is argued to mark-
edly raise both the resting level of extracellular dopamine 
and the pulsatile dopamine output, thereby causing wide-
spread stimulation of postsynaptic dopamine receptors, over-
coming the presynaptic inhibition of further neurotransmitter 
release, and triggering generalized stimulation of the nervous 
system (for a review see [42, 43]).  
“Saliency Enhancing” Model 
  Volkow and colleagues [56] suggest that the therapeuti-
cal relevance of subcortical DAT blockade by MPH is based 
on two mechanisms. For one thing, dopamine is known to 
decrease background firing of striatal neurons while streng-
thening corticostriatal signals. Thereby, amplification of ex-
tracellular dopamine levels increases the signal-to-noise ratio
in striataltargetneurons [26]. In individuals with ADHD, the 
MPH-induced amplification of the striatal dopamine signal 
could thus improve attention and reduce distractibility. For 
another thing, mesolimbic dopamine signals the saliency of 
stimuli and drives motivation to perform goal-directed be-
havior (for a review see [24, 41]). Volkow et al. [56] hy-
pothesize that in individuals with ADHD, the amplification 
of the dopamine signal could cause an increased perception 
of a stimulus as salient, thus motivating the individual to 
engage in a specific task, and improving attention and per-
formance. 
  To test their hypothesis, Volkow and colleagues used 
Positron Emission Tomography (PET) and the dopamine 
D2-like receptor radiotracer [
11C]raclopride. [
11C]raclopride 
competes with endogenous dopamine for access to subcorti-
cal (predominantly basal ganglia) dopamine D2-like recep-
tors. PET studies using this tracer provide an indirect meas-
ure of changes in synaptic dopamine levels. In a first study 
[54], ten healthy participants were administered either a 
20mg dose of oral MPH or placebo. They were then pre-
sented appetitive food stimuli (visual and olfactory presenta-
tion of food items) and neutral stimuli (description of family 
genealogy). Participants additionally gave self-reports for 
their „desire for the food“ and „hunger“. MPH significantly 
increased dorsal striatal dopamine when given with salient 
food stimuli, but not when given with neutral stimuli. No 
such differences between the two types of stimuli were found 
after placebo administration. Stimulus presentation alone 
was therefore not strong enough to significantly increase 
striatal dopamine. MPH as compared to placebo also in-
creased ratings of “desire for the food” and “hunger”, and 
these increases were correlated with dorsal striatal dopamine 
levels. In a second study [59], sixteen healthy participants 
were again administered either a 20mg dose of oral MPH or 
placebo. They then performed either an academic task 
(mathematical problems with monetary reinforcement) or a 
neutral task (passive viewing of nature pictures without re-
muneration). Participants additionally gave self-reports of 
how “exiting”, “interesting” and “motivating” they found the 
task. MPH significantly increased striatal dopamine only 
when given with the academic task. Again, no such differ-
ences between the two types of tasks were found after pla-
cebo administration. MPH as compared to placebo again 
increased rating of the task as “exiting”, “interesting” and 
“motivating”, and these increases were correlated with stri-
atal dopamine levels. These findings support the hypothesis 
that by amplifying the dopamine signal, MPH increases the 
perception of a stimulus or task as salient. The enhanced 
interest for the task could increase attention and improve 
performance [56]. 
Contribution of Prefrontal Noradrenaline 
  Much of the ADHD field has focused on subcortical do-
paminergic mechanisms in explaining the therapeutic rele-
vance of MPH. However, there is general agreement that 
ADHD involves weakened prefrontal cortex (PFC) function 
[3]. Deficits in PFC function are typically associated with 
hyperactivity, poor impulse control, distractibility, forgetful-
ness and poor organization/planning [48], all of which con-
stitute symptoms of ADHD. Imaging studies have shown 
that MPH produces more efficient PFC function in ADHD 
patients and healthy controls [36, 53]. While both dopamine 
and noradrenaline have critical influence on PFC cognitive 
functioning, there are relatively low DAT levels in the PFC 
[7], a fact accentuating the potential importance of the neuro-
transmitter noradrenaline in MPH’s therapeutic actions. In-
deed, recent biochemical studies using low doses of MPH 
showed more potent effects of the drug on hippocampal 
noradrenaline than on striatal dopamine [30], while increas-
ing both noradrenaline and dopamine release in the PFC [5]. 
Indirect support for MPH’s noradrenergic actions also comes 
from the finding that ADHD symptoms can be recreated by 
blocking  2 adrenoceptors in the monkey PFC using yo-
himbine infusions [33, 34].
  To examine the effects of low, clinically relevant MPH 
doses on PFC function in rats, Arnsten and Dudley [2] tested 
the animals on a spatial delayed alteration task, a classical 
working memory task of PFC function in rodents. To exam-
ine whether dopamine D1-like receptors and/or noradrenaline 
2 adrenoceptor actions contributed to the effects of MPH on 
PFC function, either a D1-like or an 2 antagonist was co-
administered. Results revealed that therapeutically relevant 
doses of MPH improved delayed alternation performance, 
and that this improvement likely reflected enhanced PFC 
cognitive function, since there were no changes in response 
time characteristics of motor or motivational changes. Both 
the D1-like and the 2 antagonists reversed the cognitive-
enhancing effects of MPH. Although it cannot be said with 
certainty that the cognitive-enhancing MPH effects actually 
did occur in the PFC, Berridge et al. [5] provide additional 
animal data supporting this hypothesis. Using in vivo mi-
crodialysis in rats, the authors examined the degree to which 
clinically relevant MPH doses influenced dopamine and 
noradrenaline neurotransmission within the PFC as opposed 
to the subcortical nucleus accumbens. Again, the adminis-
tered MPH doses improved sustained attention and working 
memory while having minimal effects on locomotion and 
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noradrenaline efflux in the nucleus accumbens and PFC. 
However, MPH had substantially smaller effects on dopa-
mine efflux in the nucleus accumbens, and it produced sub-
stantially larger noradrenaline than dopamine efflux in the 
PFC. 
  The current data are consistent with the hypothesis that at 
clinical doses, MPH improves performance by increasing the 
availability of dopamine and noradrenaline, which in turn 
stimulate D1-like and 2 receptors, preferentially within the 
PFC. Importantly, these data indicate that the noradrenergic 
prefrontal actions of MPH are just as important as the drug’s 
dopaminergic effects. 
ASSESSING THE COMBINED IMPACT OF MPH 
AND REWARD IN HEALTHY CONTROL PARTICI-
PANTS 
  The activity-reducing property of low-dose MPH is well 
established in the treatment of hyperactive children. Low-
dose MPH also suppresses locomotor activity in the rat under 
conditions associated with elevated arousal [31]. Aim of the 
following study was to examine whether MPH would ac-
cordingly unfold its activity-reducing property in behavior-
ally aroused healthy participants [14]. For this purpose, 41 
male university students accomplished a card-sorting task 
using monetary reward in a double-blind, placebo-controlled, 
between-group study design. We examined how behavioral 
activity in the card-sorting task was influenced (a) by mone-
tary reward, which we expected to initiate phasic dopamine 
release in striatal structures [27, 28], (b) by a low therapeutic 
(20mg) dose of oral MPH, which we expected to enhance 
tonic dopamine availability and (c) by the combination of the 
two “stimulants”. We hypothesized to find an increase in 
behavioral activity in the reward as compared to the non-
reward condition. According to Seeman and Madras’ hy-
pothesis of biphasic MPH action, this reward-induced in-
crease in behavioral activity should be lower after MPH as 
compared to placebo administration. 
  Aiming to acquire simple output measures of behavioral 
activity and performance accuracy, we assessed the numbers 
of total, correct and incorrect responses, and the success rate 
achieved in the task. Behavioral activity was represented by 
the number of total responses (composed of the number of 
correct and incorrect responses). Performance accuracy was 
represented by the number of errors and the success rate (de-
fined as the ratio of correct to total responses). The card-
sorting task comprised a non-reward and a reward condition. 
During the reward condition participants received 0.10$ for 
every correct response. The total reward could amount up to 
12$.  
  Data analysis revealed that reward alone improved per-
formance accuracy in the utilized card-sorting task by in-
creasing the participants’ success rate (increasing the number 
of correct responses and decreasing the number of incorrect 
responses). MPH inhibited a reward-induced increase in both 
behavioral activity and performance accuracy by decreasing 
the achieved number of total and correct responses and con-
sequently decreasing the success rate to the non-reward 
level. MPH thus equalized non-rewarded and rewarded per-
formance (see Fig. 1). 
  To the best of our knowledge, this is the first study to 
demonstrate MPH’s activity-reducing action in healthy par-
ticipants. Although dopamine levels were not directly meas-
ured, the results support the notion that MPH produces 
biphasic effects via modulation of tonic and phasic dopa-
mine. In accordance with Seeman and Madras’ hypothesis of 
biphasic MPH action [42, 43], heightened striatal tonic do-
pamine levels following drug challenge might have acted 
primarily on presynaptic dopamine autoreceptors. In turn, 
these autoreceptors might have initiated the relative reduc-
tion of stimulus-induced pulsatile transmitter release. A re-
ward-induced increase in response-activity – determining the 
number of total and correct responses – might have conse-
quently been inhibited. It is a limitation of this study that 
only one dose of MPH was tested. To ensure our conclusion 
of biphasic MPH action, a low and a high drug dose should 
have been tested against each other. 
  This study was not designed to test Volkow and col-
league’s “saliency enhancing” model in parallel. It would 
have been necessary to measure the influence of MPH on the 
Fig. (1). Means and standard errors for the interaction effect of reward and treatment on performance. Post-hoc simple main effects analyses 
revealed that after placebo as compared to methylphenidate (MPH) administration, a) the number of total responses (p=.02), b) the number of 
correct responses (p<.001) and c) the success rate (p<.001) were increased with reward. MPH thus inhibited a reward-induced increase in 
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participants’ rating of task saliency as well as their motiva-
tion to engage in the task. According to Volkow et al., these 
measures should have been linked to attention and perform-
ance. Thus, rather than finding an attenuation in the number 
of correct responses, an increase in the number of correct 
responses and in success rate would have been expected with 
reward and MPH. Future investigations should be designed 
such that Volkow et al.’s “saliency enhancing” model [56] 
and Seeman and Madras’ hypothesis of biphasic MPH action 
[42, 43] can be tested against each other. 
CONCLUSION 
  Despite the widespread use of MPH in the treatment of 
ADHD, the neural mechanisms underlying the drug’s clini-
cal actions are under debate. In this review, we summarized 
the three most discussed theories involving the catechola-
minergic system. 
  Typically, each of these theories is discussed as exclu-
sive. However, especially the neurochemical mechanisms 
suggested by Volkow and colleagues [56] and Seeman and 
Madras [42, 43] may be complimentary. Volkow et al. sug-
gest that MPH amplifies stimuli-induced dopamine increases 
in magnitude and duration. Seeman and Madras, on the other 
hand, argue that the pulsatile dopamine surge elicited by a 
salient stimulus is decreased following the administration of 
a therapeutic MPH dose. Yet, the pulsatile dopamine surge is 
thought to be only relatively lower than it would have been 
in the absence of the drug (approximately threefold lower). 
Given the four possible states of extracellular dopamine lev-
els a) at rest, b) during a nerve impulse, c) after MPH stimu-
lation, and d) during a nerve impulse after MPH stimulation, 
the total amount of extracellular dopamine measurable in the 
striatum should be highest when a stimulus-triggered neuro-
transmitter release succeeds MPH challenge (approximately 
twofold higher than in the absence of the drug) [43]. Thus, 
the imaging results as found by Volkow et al. [54, 59] – an 
increase in striatal dopamine only if the dopamine-releasing 
effect of MPH is combined with either a salient food stimu-
lus or task – would likewise be predicted by Seeman and 
Madras’ hypothesis.  
  The main difficulty in integrating findings of subcortical 
and prefrontal MPH effects lies in the lacking comparability 
of available research methods. Whereas our knowledge of 
subcortical MPH effects stems mainly from imaging studies 
in humans using PET and the dopamine D2-like receptor 
radiotracer [
11C]raclopride, MPH’s prefrontal actions are 
examined in the animal model using microdialysis. It can 
however be assumed that both the subcortical and prefrontal 
actions of MPH are implicated in its therapeutical action. 
Several researchers have effectively suggested basal ganglia 
and prefrontal cortex to be differentially involved in the mo-
tor and cognitive symptoms of ADHD (for a review see [12, 
21, 45]), thus explaining differences in the specific efficacy 
of current dopaminergic and noradrenergic medication (for a 
review see [32]). On the basis of his tonic/phasic model of 
dopamine system regulation, Grace [21] thus argues that 
reduced stimulation from the prefrontal cortex determines 
lowtonic dopamine activity in subcortical regions. Low tonic 
stimulation of inhibitory autoreceptors may in turn trigger 
increased phasic activity, which may again result in dysregu-
lated motor and impulse control in ADHD patients. Aiming 
at the validation of this hypothesis, it would be of interest to 
repeat our test paradigm in a sample of ADHD patients with 
and without symptoms of hyperactivity, and to examine 
whether the achieved responsivity patterns dissociate be-
tween both types of the disorder. 
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